Update on molecular findings, management and outcome in low-grade gliomas.
about
One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literatureEpigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumorsComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.Genetics and imaging of oligodendroglial tumors.A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.Investigation of adhesion and mechanical properties of human glioma cells by single cell force spectroscopy and atomic force microscopy.Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes.MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1.TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.Combination genetic signature stratifies lower-grade gliomas better than histological grade.Association of carcinoid tumor and low grade glioma.Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomasVelocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas.Microsomal membrane proteome of low grade diffuse astrocytomas: Differentially expressed proteins and candidate surveillance biomarkers.Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.Mutations in epigenetic regulators in myelodysplastic syndromes.Long-term epilepsy-associated tumors.IDH mutations in human gliomaDiagnosis of oligodendroglioma: molecular and classical histological assessment in the twenty-first century.Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail.Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm.LncRNAs: new players in gliomas, with special emphasis on the interaction of lncRNAs With EZH2.Epilepsy associated tumors: Review article.The role of surgery in grade II/III oligodendroglial tumors.Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.The renal v-ATPase a4 subunit is expressed in specific subtypes of human gliomas.Focal herpes zoster encephalitis without a rash: diagnostic confusion between astrogliosis and low-grade glioma.Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas.Integrins and p53 pathways in glioblastoma resistance to temozolomide.Second Surgery in Insular Low-Grade Gliomas.A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma.ATRX immunostaining predicts IDH and H3F3A status in gliomas.Comprehensive Genomic Analysis of Infiltrative Gliomas Based on Molecular Profile.MET gain in diffuse astrocytomas is associated with poorer outcome.
P2860
Q26863688-1673D443-6761-412B-9A9F-A936DA0E5F3DQ26864920-C50F70E7-A5FE-411A-A03D-F1DAB9DAC381Q27853175-FF591F6C-D294-4871-A89C-DD977C66FEBFQ30458648-DE5DE714-63BC-4A62-BE5D-68DC58AE71E3Q30542081-21B80192-CBC4-474F-89E5-270D01044DA7Q31007575-7C4E874E-FEAB-4431-BDAB-67B3B09C6317Q33764533-F0A51379-6D02-4B09-B25E-CD81F4DBAC40Q34497830-D6203A86-C94E-4159-989D-2F9B79A25991Q34625644-BD48D9A9-777D-44C0-B4A2-7AD60C680859Q35418206-B1E74361-E040-422C-BBB9-1146E4092B6DQ35559086-23B2C4DE-03EF-4D6C-B28E-CCCB9BAAF122Q35839826-F98D6E35-927C-4054-98C4-1E6F51CE9349Q36261882-72CD59F9-0E4B-44A9-8439-94AE22A456F5Q36356194-D631B50D-7789-4A30-AEA2-91BCB8D7BF0CQ36406843-0664ACA0-60AC-47BA-93B4-4A7EA8E27C4BQ36785136-F84ACB42-7CD7-48A3-A7EE-CBCB78894ECDQ36792738-56BF9057-094A-4D09-8D32-98658CE0D00CQ36953938-3ADDB6E7-F895-49FD-9C6C-392723DA2983Q37580501-814FF4CA-4B8C-48E9-98A7-3E5150371048Q37662100-6DBD89AB-2E4D-4F54-9FCB-396957183DF6Q37974844-F83D0695-7E90-42A8-A66B-026D465F44C9Q38002123-CB686725-13CB-4D88-9318-ABBF5F093564Q38022856-9F4B0095-9EC9-463C-AE04-45AEC8140BF3Q38035066-627A76E8-D9C1-4F15-91A5-9A6CB50F01ADQ38083799-F765F99A-F010-4B8F-AD75-E95B3BF867F7Q38125816-0DDB57DC-707C-4055-9D43-7537FC57D9F0Q38176848-CE5C33B5-0F73-40D5-9CDE-B17F8CCD2788Q38269055-5B3C0194-20A8-4140-9472-66237A2B7859Q38610485-91BEAA98-0C4F-450C-8475-95BE1C72FA3FQ38890122-5FE0C2DE-4FB3-4CF4-BA60-5D9A97804F95Q39372069-BC00D202-0070-4E61-8FFB-9DBA90AEDBB2Q40539023-C6399D61-6BC3-45D2-896C-7C3E43009ADCQ41201032-AEF4C059-A219-46D6-9F4F-906124210A02Q41393365-FBED46E5-F2F5-45E9-B18C-B6A1D8A1DF5BQ41630032-3193A9EA-8561-4A09-B60F-FE8559F63EB1Q42227115-19E0F15E-663C-423A-8FD6-B0F58CE4CB95Q42290163-65B4C3EE-1BF0-4264-BF8E-5C320A2CEBE6Q42701263-9FC72825-8E1D-40AB-9FE9-ED312F1F333AQ45029683-33C5A128-1EDC-4E6E-AC44-790C720F05CDQ45839064-D70BDD61-64EC-4480-8913-E27AAADD2119
P2860
Update on molecular findings, management and outcome in low-grade gliomas.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Update on molecular findings, management and outcome in low-grade gliomas.
@ast
Update on molecular findings, management and outcome in low-grade gliomas.
@en
type
label
Update on molecular findings, management and outcome in low-grade gliomas.
@ast
Update on molecular findings, management and outcome in low-grade gliomas.
@en
prefLabel
Update on molecular findings, management and outcome in low-grade gliomas.
@ast
Update on molecular findings, management and outcome in low-grade gliomas.
@en
P2860
P1476
Update on molecular findings, management and outcome in low-grade gliomas.
@en
P2093
David Schiff
T David Bourne
P2860
P2888
P304
P356
10.1038/NRNEUROL.2010.159
P407
P577
2010-11-02T00:00:00Z
P5875
P6179
1026853007